Period:
Draw Mode:
| Volume | 476,589 |
|
|||||
| News | - | ||||||
| Day High | 10.72 | Low High |
|||||
| Day Low | 10.15 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Immatics NV | IMTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.31 | 3.02% | 10.59 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 10.29 | 10.15 | 10.72 | 10.59 | 10.28 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 4,634 | 476,589 | $ 10.55 | $ 5,025,774 | - | 5.90 - 13.60 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:01:17 | 1 | $ 10.75 | USD |
Immatics NV Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 811.94M | 76.67M | 56.72M | $ - | $ - | 0.56 | 14.90 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | - | - |
Immatics NV News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IMTX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 9.84 | 10.72 | 9.59 | 10.11 | 622,329 | 0.75 | 7.62% |
| 1 Month | 9.73 | 10.72 | 9.171 | 9.94 | 360,550 | 0.86 | 8.84% |
| 3 Months | 7.84 | 10.72 | 5.90 | 8.42 | 446,863 | 2.75 | 35.08% |
| 6 Months | 11.15 | 11.45 | 5.90 | 8.51 | 308,528 | -0.56 | -5.02% |
| 1 Year | 7.99 | 13.60 | 5.90 | 9.44 | 260,576 | 2.60 | 32.54% |
| 3 Years | 17.25 | 19.00 | 5.75 | 11.18 | 248,710 | -6.66 | -38.61% |
| 5 Years | 17.25 | 19.00 | 5.75 | 11.18 | 248,710 | -6.66 | -38.61% |
Immatics NV Description
| Immatics NV is engaged in the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's pipeline consists of two lead product classes, engineered Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics (TCER). Each therapeutic modality has distinct attributes to produce the desired therapeutic effect for patients at different disease stages and with different types of tumors focusing on particularly hard-to-treat solid cancers. |